Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Candesartan cilexetil
Drug ID BADD_D00347
Description Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Indications and Usage Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197.
Marketing Status Prescription; Discontinued
ATC Code C09CA06
DrugBank ID DB00796
KEGG ID D00626
MeSH ID C077793
PubChem ID 2540
TTD Drug ID Not Available
NDC Product Code 62559-640; 0378-3224; 62559-643; 62332-341; 49884-659; 0378-3225; 72761-002; 49884-660; 62559-641; 63629-2127; 46708-342; 49884-661; 0378-3232; 68382-191; 70771-1204; 63629-2126; 17228-0032; 62332-342; 70518-2719; 0378-3231; 60687-119; 62332-343; 46708-060; 70771-1207; 60687-241; 70771-1205; 68382-190; 17228-0017; 46708-343; 68382-192; 62559-642; 68382-193; 49884-658; 62332-060; 46708-877; 70771-1206; 17228-0016; 17228-0018; 70518-2884; 64220-114; 60687-130; 46708-341; 52562-100; 65372-1128
Synonyms candesartan cilexetil | 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate | 1H-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)- | Parapres | Kenzen | Amias | Blopress | Atacand | TCV 116 | TCV-116
Chemical Information
Molecular Formula C33H34N6O6
CAS Registry Number 145040-37-5
SMILES CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC 6
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute kidney injury20.01.03.0160.092515%
Foetal growth restriction18.03.01.0020.001508%
Hepatocellular carcinoma16.07.02.005; 09.04.02.0100.001006%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.011564%Not Available
Diffuse alopecia23.02.02.0070.003855%Not Available
Pneumocystis jirovecii pneumonia11.03.07.005; 22.07.08.0090.001508%Not Available
Mouth swelling07.05.04.007; 23.04.01.020; 10.01.05.0200.009637%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.001006%
Cornea verticillata06.06.03.0160.005782%Not Available
Bladder transitional cell carcinoma20.03.04.003; 16.08.01.0020.003855%Not Available
Coeliac disease14.02.01.007; 10.04.04.012; 07.17.01.0080.003855%Not Available
Renal dysplasia20.01.06.013; 03.06.01.0130.001508%Not Available
Renin increased13.09.02.0040.003855%Not Available
Small for dates baby18.04.02.0020.007710%Not Available
Congenital renal disorder20.01.02.015; 03.06.01.0080.001006%Not Available
Vasoplegia syndrome24.06.03.011; 12.02.01.0100.003855%Not Available
Quality of life decreased13.18.01.0130.005782%Not Available
Facial asymmetry15.10.05.0040.003855%Not Available
Portal hypertensive enteropathy09.01.06.021; 07.12.03.009; 24.08.06.0050.003855%Not Available
Traumatic haemothorax12.01.03.010; 24.07.01.085; 22.05.02.0080.003855%Not Available
Tendon discomfort15.07.01.0120.005782%Not Available
Hypoosmolar state14.05.01.0100.003855%Not Available
The 15th Page    First    Pre   15    Total 15 Pages